Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis

References

• Comenzo R L. Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 2006; 7: 182–185
   PubMedGoogle Scholar
• Kyle R A, Gertz M A, Greipp P R, Witzig T E, Lust J A, Lacy M Q, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207
   PubMed Web of Science ®Google Scholar
• Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290–298
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Hussein M A, Rasmussen E, Solomon A, Larson R A, Crowley J J, United States Intergroup Trial Southwest Oncology Group. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520–3526
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright D G, Rosenzweig M, Finn K T, Fennessey S, Zeldis J B, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492–496
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949–2951
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy M Q, Rajkumar S V, Geyer S M, Witzig T E, Fonseca R, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257–261
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy M Q, Zeldenrust S R, Hayman S R, Kumar S K, Geyer S M, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465–470
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin D C, Dember L M, Falk R H, Berk J L, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93
   PubMed Web of Science ®Google Scholar
• Comenzo R L. Current and emerging views and treatments of systemic immunoglobulin light-chain (AL) amyloidosis. Contrib Nephrol 2007; 153: 195–210
   PubMedGoogle Scholar
• Vesole D H, Perez W S, Akasheh M, Boudreau C, Reece D E, Bredeson C N, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006; 81: 880–888
   PubMed Web of Science ®Google Scholar
• Goodman H J, Gillmore J D, Lachmann H J, Wechalekar A D, Bradwell A R, Hawkins P N. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006; 134: 417–425
   PubMed Web of Science ®Google Scholar
• Bahlis N J, Lazarus H M. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?. Bone Marrow Transplant 2006; 38: 7–15
   PubMed Web of Science ®Google Scholar
• Perz J B, Rahemtulla A, Giles C, Szydlo R M, Davis J, Gopaul D, et al. Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2006; 37: 937–943
   PubMed Web of Science ®Google Scholar
• Chow L Q, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, et al. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant 2005; 36: 591–596
   PubMed Web of Science ®Google Scholar
• Mollee P N, Wechalekar A D, Pereira D L, Franke N, Reece D, Chen C, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004; 33: 271–277
   PubMed Web of Science ®Google Scholar
• Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853–855
   PubMed Web of Science ®Google Scholar
• Jantunen E, Itala M, Lehtinen T, Kuittinen O, Koivunen E, Leppa S, et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 2006; 76: 245–250
   PubMed Web of Science ®Google Scholar
• Kristen A V, Meyer F J, Perz J B, Schonland S O, Hundemer M, Hegenbart U, et al. Risk stratification in cardiac amyloidosis: novel approaches. Transplantation 2005; 80(Suppl)S151–S155
   PubMed Web of Science ®Google Scholar
• Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 2004; 11: 245–256
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R A, Gertz M A, Therneau T M, Miller W L, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787–1789
   PubMed Web of Science ®Google Scholar
• Wallace T W, Abdullah S M, Drazner M H, Das S R, Khera A, McGuire D K, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113: 1958–1965
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Vosburgh E, Falk R H, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–3670
   PubMed Web of Science ®Google Scholar
• Comenzo R L. Managing systemic light-chain amyloidosis. J Natl Compr Cancer Net 2007; 5: 179–187
   PubMedGoogle Scholar
• Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938
   PubMed Web of Science ®Google Scholar
• Wechalekar A D, Goodman H J, Lachmann H J, Offer M, Hawkins P N, Gillmore J D. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–464
   PubMed Web of Science ®Google Scholar
• Wechalekar A D, Gillmore J, Lachmann H J, Offer M, Hawkins P N. Efficacy and safety of bortezomib in systemic AL amyloidosis: a preliminary report. Blood (Suppl.) 2006; 108: 129
   Google Scholar
• Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French Multicentric Randomized Trial (MAG and IFM Intergroup). Blood (Suppl.) 2005; 106: 421
   Google Scholar
• Dispenzieri A, Lacy M Q, Kyle R A, Therneau T M, Larson D R, Rajkumar S V, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001; 19: 3350–3356
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Hayman S R, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007; 19: 136–141
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R A, Lacy M Q, Therneau T M, Larson D R, Plevak M F, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960–3963
   PubMed Web of Science ®Google Scholar
• Seldin D C, Anderson J J, Sanchorawala V, Malek K, Wright D G, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888–1893
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Gastineau D A, Chen M G, Ansell S M, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002; 113: 549–555
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy M Q, Katzmann J A, Rajkumar S V, Abraham R S, Hayman S R, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378–3383
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright D G, Quillen K, Fisher C, Skinner M, Seldin D C. Early serum free light chain responses following high-dose melphalan and stem cell transplantation for AL amyloidosis predict treatment outcomes. Blood (Suppl.) 2005; 106: 1160
   Google Scholar
• Leung N, Leung T R, Cha S S, Dispenzieri A, Lacy M Q, Gertz M A. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005; 106: 3353–3357
   PubMed Web of Science ®Google Scholar
• Porrata L F, Gertz M A, Litzow M R, Lacy M Q, Dispenzieri A, Inwards D J, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11: 1210–1218
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440–2445
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M A, Kyle R A, Lacy M Q, Burritt M F, Therneau T M, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881–1887
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M A, Kyle R A, Lacy M Q, Burritt M F, Therneau T M, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751–3757
   PubMed Web of Science ®Google Scholar
• Leung N, Dispenzieri A, Lacy M Q, Hayman S R, Kumar S, Gertz M A. Risk factors of treatment related mortality during autologous stem cell transplant in patients with light chain associated amyloidosis (AL). Blood (Suppl.) 2006; 108: 3082
   Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Ansell S M, Elliott M A, Gastineau D A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025–1031
   PubMed Web of Science ®Google Scholar
• Comenzo R L, Gertz M A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282
   PubMed Web of Science ®Google Scholar